[
  {
    "ts": "2026-02-24T01:50:00+00:00",
    "headline": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
    "summary": "Is this the best way to cash in on the weight-loss gold rush?",
    "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
      "content": {
        "id": "b570b168-e5bd-3c20-8f00-9f73b1936546",
        "contentType": "STORY",
        "title": "Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.",
        "description": "",
        "summary": "Is this the best way to cash in on the weight-loss gold rush?",
        "pubDate": "2026-02-24T01:50:00Z",
        "displayTime": "2026-02-24T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "A person surrounded by stock monitors stands with both fists raised in the air.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3yBXzk4FUvsgR0VJ93gOsA--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3weefRt6VjSNRthUdJc8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8cb3e7d41323dda7fd999091cfad559b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/23/got-5000-viking-therapeutics-might-be-a-weightloss/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/got-5-000-viking-therapeutics-015000209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T03:12:53+00:00",
    "headline": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
    "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
    "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
      "content": {
        "id": "16955788-3c9d-3a6f-8da1-ee8f9f9ef0d2",
        "contentType": "STORY",
        "title": "CagriSema Setback Tests Novo Nordisk Obesity Ambitions And Growth Story",
        "description": "",
        "summary": "Novo Nordisk (CPSE:NOVO B) reported that its next generation obesity drug candidate CagriSema did not meet the primary goal of non inferiority versus Eli Lilly's tirzepatide in a head to head Phase 3 trial. The readout from this pivotal study challenges Novo Nordisk's efforts to strengthen its position in the competitive market for injectable weight loss therapies. The result introduces fresh questions around CagriSema's commercial potential and the company's roadmap for future obesity...",
        "pubDate": "2026-02-24T03:12:53Z",
        "displayTime": "2026-02-24T03:12:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pVOKMAerbRsXv56pHka6Lw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmyGBi4taxQExvvwka_9KQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cagrisema-setback-tests-novo-nordisk-031253330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]